UTIs, Hidden Symptoms & a New Hot Flash Drug Worth Knowing About
Quick Summary
This episode covers three things: a USA Today investigation into menopausal women dying from UTIs the FDA had warned about, a conversation about the menopause symptoms that catch women completely off guard, and new clinical data on elinzanetant — a non-hormonal drug cutting hot flash frequency by half. All three are about knowing what menopause actually does to your body, so you can advocate for yourself in a medical system that often misses it.
UTIs, Hidden Symptoms & a New Hot Flash Drug Worth Knowing About
Key Takeaways
- ✦Menopausal women are at significantly higher risk for recurrent UTIs because lower estrogen thins the tissue lining the urinary tract, making it easier for bacteria to take hold — and harder to clear infections.
- ✦The USA Today investigation found the FDA had documented warnings about UTI-related deaths in menopausal women, raising serious questions about how urgently that information reached patients and their doctors.
- ✦Menopause causes symptoms well beyond hot flashes and night sweats — including itchy skin, electric shock sensations, tinnitus, and changes in body odor — that many women and doctors don't connect to menopause at all.
- ✦Elinzanetant, a non-hormonal drug that works by blocking a brain signaling pathway involved in temperature regulation, reduced hot flash frequency by about 50% in clinical trial data presented with Dr. JoAnn Pinkerton.
- ✦A 50% reduction in hot flash frequency is meaningful, but what matters for each woman is what that looks like in her specific life — going from 10 hot flashes a day to 5 is real relief; going from 2 to 1 less so.
Sources & References
Episode Script
Thanks Toni. We've got a lot to get into today.
A USA Today investigation dropped this week about menopausal women dying from UTIs — urinary tract infections — and the FDA's role in what happened, or didn't happen, when warnings started coming in. This one matters, so I want to give it real space.
If you've been through perimenopause or menopause, there's a decent chance UTIs are already on your radar. Recurrent UTIs are genuinely one of the more common and genuinely disruptive things that happens to women at this stage of life. The reason comes down to estrogen — specifically, what happens when you have less of it. The tissue lining your urinary tract and vagina depends on estrogen to stay thick, elastic, and well-populated with the kind of bacteria that keeps harmful bugs from gaining a foothold. When estrogen drops, that tissue thins out. The environment changes. Bacteria that used to have a hard time getting in now have a much easier time — and once you've had one UTI, the conditions that allowed it are still there, which is why they tend to come back.
For most women, a UTI is miserable but manageable. Antibiotics, done. But for some women — particularly older women, or women with other health conditions, or women whose infections keep recurring and keep getting treated without anyone addressing the underlying cause — things can go wrong in a serious way. Infections can spread. They can become resistant to the antibiotics being used. And in some cases, they have been fatal.
The USA Today investigation found that the FDA had received warnings about this. Documented signals. And the question the reporting raises — pointedly — is what happened with those warnings and how quickly the urgency translated into clearer guidance for patients and the clinicians treating them.
I'm not going to speculate beyond what the reporting says, because this story is still developing and I want to be careful not to get ahead of the evidence. But I'll say this plainly: if you are having recurrent UTIs, that is a menopause conversation, not just an antibiotic conversation. The underlying cause — lower estrogen affecting the tissue of your urinary and vaginal tract — has treatments. Local vaginal estrogen, specifically, has really solid evidence behind it. It's low-dose, it stays local, it's not the same risk calculus as systemic hormone therapy, and it can genuinely change the pattern for women who keep cycling through infections. The kind of evidence your doctor would look at on a tool like OpenEvidence supports this clearly.
The frustrating part — and this connects directly to the investigation — is that many women are never told this is an option. They get the antibiotic prescription and they go home. And three months later they're back. The tissue problem is never addressed because the conversation about menopause and what it does to the urinary tract never happens.
That's a medical system failure. It's not about bad intentions. It's about doctors who weren't trained to connect these dots, appointments too short to cover everything menopause touches, and a cultural habit of treating symptoms in isolation rather than looking at what's driving them. This investigation, whatever the full regulatory story turns out to be, is a reason to push for that conversation.
If recurrent UTIs are part of your life right now, ask your doctor specifically about genitourinary syndrome of menopause — that's the umbrella term for all the changes that happen to your vaginal and urinary tissue when estrogen drops — and ask whether local vaginal estrogen is appropriate for you. That's not a prescription, that's a question worth asking.
Recurrent UTIs don't get nearly enough airtime as a menopause symptom, which is part of a bigger pattern. There are a lot of things menopause does to the body that women don't see coming, because they're not in the standard script of "hot flashes, night sweats, mood changes, irregular periods." Dr. Lauren Streicher's podcast this week featured Dr. Makeba Williams talking specifically about what she calls esoteric symptoms of menopause — and I want to spend a few minutes here because this is genuinely useful territory.
The word esoteric here doesn't mean rare. Dr. Williams makes that distinction clearly: an unusual symptom is something that rarely happens. An esoteric symptom is something that happens commonly but isn't talked about and isn't well understood. That's a real difference, and it's why so many women end up feeling like something is wrong with them specifically, rather than recognizing that what they're experiencing is part of a recognized pattern.
Some examples from the conversation: itchy skin, particularly without a rash — women describe it as an internal itch, like it's under the skin rather than on the surface. Changes in body odor. Tinnitus, which is ringing in the ears. That strange sensation some women describe as an electric shock or a "brain zap" right before a hot flash. Dry eyes. Gum and dental changes. The feeling that your mouth tastes different or that food tastes different. Formication — that's the medical term for the sensation of something crawling on or under the skin. Disturbing or unusually vivid dreams.
None of these are in the pamphlet. And so women go to a dermatologist for the itchy skin, or an ENT for the tinnitus, or a dentist for the gum changes, or they just quietly wonder what's happening to them — and no one connects it back to menopause. Meanwhile, the underlying hormonal shift is driving all of it.
This matters for a few reasons. One is practical: if you know these things are menopause symptoms, you're in a better position to have the right conversation with the right doctor. The other reason is psychological, honestly. There is something genuinely relieving about having a name for an experience. It doesn't fix it, but it changes the relationship you have with it. It moves it from "am I falling apart" to "this is a thing that happens, and here's why."
The list of what menopause touches is so much longer than most women are prepared for. That's not meant to be alarming — it's meant to be useful. The more accurately you can describe what you're experiencing, the better any clinician can help you.
The third thing worth your attention today is a drug called elinzanetant. Contemporary OB/GYN published coverage of data presented with Dr. JoAnn Pinkerton — she's a well-regarded menopause specialist — showing a roughly 50% reduction in hot flash frequency for women taking elinzanetant in clinical trials.
Elinzanetant is non-hormonal. It doesn't add estrogen or progesterone to your system. What it does is block a specific signaling pathway in the brain — involving something called the NK3 receptor — that researchers believe plays a role in triggering hot flashes. The body's temperature regulation system essentially misfires during menopause, and this drug targets a part of the mechanism that causes that misfiring. That's a genuinely different approach from what's been available.
A 50% reduction in frequency sounds significant, and it is. But I want to be precise about what that actually means for different women. If you're having ten hot flashes a day and that drops to five, that is meaningful, life-affecting relief. If you're having two and that drops to one, that's also technically a 50% reduction, but it's going to feel very different in your daily life. The number is real; the context around it is what determines whether it's right for any particular person.
Elinzanetant is not the first drug in this class — fezolinetant got FDA approval in 2023 and works through a similar mechanism. So this is part of an expanding category of non-hormonal options that work on the brain's temperature regulation system rather than on hormones directly. That's worth paying attention to, because it broadens the realistic options for women who can't or don't want to use hormone therapy.
My actual read on this: the data looks legitimately promising, and I think this category of drugs has been underexplained to the public relative to its potential impact. The conversation about non-hormonal options has historically defaulted to antidepressants — which do work for some women but come with their own set of trade-offs — or herbal supplements, which mostly don't have the evidence to back them up. A drug targeting the specific neural pathway involved in hot flashes is a meaningfully different kind of tool. The clinical trial data needs to continue holding up as more women use it in the real world, but what's been published so far is worth taking seriously.
If you're managing hot flashes and hormone therapy isn't on the table for you — or you've tried it and it wasn't the right fit — this is a conversation to bring to your doctor. Ask about elinzanetant specifically, and ask how the data compares to fezolinetant, since both are now in this space and your doctor's familiarity with one versus the other may vary.
Sources curated automatically by the Hot Flasher pipeline.
Hot Flasher provides informational content only and does not constitute medical advice. Always consult a qualified healthcare provider for medical concerns.